NicOx S.A. today announced that additional naproxcinod clinical data were presented at the Annual European Congress of Rheumatology, the annual conference of the European League Against Rheumatism (EULAR), which took place from June 16 to June 19 in Rome, Italy. Two posters on clinical results for naproxcinod were presented.
Naproxcinod is the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the relief of the signs and symptoms of osteoarthritis. It is currently under review by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
For more information, please click the link below: